CDKN2B-AS1 and lung cancer: In this context, numerous studies have demonstrated the oncogenic properties of the long non-coding RNA CDKN2B-AS1 (CDKN2B antisense RNA 1, ANRIL) in multiple carcinomas, including thyroid cancer [142], gastric cancer [143], and lung cancer [144].